JP5006998B2 - Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法 - Google Patents

Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法 Download PDF

Info

Publication number
JP5006998B2
JP5006998B2 JP50061698A JP50061698A JP5006998B2 JP 5006998 B2 JP5006998 B2 JP 5006998B2 JP 50061698 A JP50061698 A JP 50061698A JP 50061698 A JP50061698 A JP 50061698A JP 5006998 B2 JP5006998 B2 JP 5006998B2
Authority
JP
Japan
Prior art keywords
cells
mhc class
cell
sequence
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50061698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511898A5 (cg-RX-API-DMAC10.html
JP2000511898A (ja
Inventor
スーザン アール ウェップ
オラ ウィンクヴィスト
ラース カールソン
マイケル アール ジャクソン
ペル エイ ピーターソン
Original Assignee
ザ スクリプス リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティチュート filed Critical ザ スクリプス リサーチ インスティチュート
Publication of JP2000511898A publication Critical patent/JP2000511898A/ja
Publication of JP2000511898A5 publication Critical patent/JP2000511898A5/ja
Application granted granted Critical
Publication of JP5006998B2 publication Critical patent/JP5006998B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
JP50061698A 1996-05-23 1997-05-22 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法 Expired - Lifetime JP5006998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1817596P 1996-05-23 1996-05-23
US60/018,175 1996-05-23
PCT/US1997/008697 WO1997046256A1 (en) 1996-05-23 1997-05-22 Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012077703A Division JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Publications (3)

Publication Number Publication Date
JP2000511898A JP2000511898A (ja) 2000-09-12
JP2000511898A5 JP2000511898A5 (cg-RX-API-DMAC10.html) 2005-01-13
JP5006998B2 true JP5006998B2 (ja) 2012-08-22

Family

ID=21786645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50061698A Expired - Lifetime JP5006998B2 (ja) 1996-05-23 1997-05-22 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法
JP2012077703A Withdrawn JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012077703A Withdrawn JP2012143245A (ja) 1996-05-23 2012-03-29 Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法

Country Status (12)

Country Link
US (4) US6355479B1 (cg-RX-API-DMAC10.html)
EP (1) EP0969865B1 (cg-RX-API-DMAC10.html)
JP (2) JP5006998B2 (cg-RX-API-DMAC10.html)
AT (1) ATE347588T1 (cg-RX-API-DMAC10.html)
AU (1) AU723355B2 (cg-RX-API-DMAC10.html)
CA (1) CA2254975C (cg-RX-API-DMAC10.html)
DE (1) DE69737070T2 (cg-RX-API-DMAC10.html)
DK (1) DK0969865T3 (cg-RX-API-DMAC10.html)
ES (1) ES2278390T3 (cg-RX-API-DMAC10.html)
IL (1) IL126843A (cg-RX-API-DMAC10.html)
PT (1) PT969865E (cg-RX-API-DMAC10.html)
WO (1) WO1997046256A1 (cg-RX-API-DMAC10.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046256A1 (en) * 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE437366T1 (de) 1998-05-11 2009-08-15 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen- spezifischen t-zellen
US6230662B1 (en) 1998-06-22 2001-05-15 Theresa Miale Animal lift and transport apparatus and method for using the same
AU5474399A (en) * 1998-08-10 2000-03-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
CA2345277C (en) 1998-10-20 2011-05-24 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2000243137A1 (en) * 2000-04-20 2001-11-07 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
DE60138922D1 (de) 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002056908A2 (en) * 2001-01-16 2002-07-25 Hildebrand William H Artificial antigen-presenting cells
AU2002255532A1 (en) * 2001-02-13 2002-10-15 Joseph D. Mosca Biological carriers for induction of immune responses
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
JP2006510567A (ja) * 2001-02-20 2006-03-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 腫瘍の治療のための細胞治療方法
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7670781B2 (en) * 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1808200A3 (en) * 2002-10-11 2007-09-19 Sentoclone AB Cancer immuno-therapy
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007511760A (ja) * 2003-11-03 2007-05-10 ベックマン コールター インコーポレーティッド Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
LT2573166T (lt) 2004-02-26 2016-09-26 Immunovative Therapies, Ltd. T ląstelių paruošimo būdas ląstelių terapijai
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2007536522A (ja) * 2004-05-07 2007-12-13 ベックマン コールター インコーポレーティッド Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Institute métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
WO2006138449A2 (en) * 2005-06-16 2006-12-28 The Wistar Institute Method for identifying a mhc class ii-dependent tumor-associated t helper cell antigen
JP5205275B2 (ja) 2005-12-21 2013-06-05 セントクローネ インターナショナル エービー 散在性ガンの治療法
WO2007071388A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
JP2009531303A (ja) * 2006-03-01 2009-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ リンパ球枯渇剤をｃｔｌおよびサイトカインと組合せる癌処置
US8124408B2 (en) * 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
NZ600281A (en) * 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
US20110092961A1 (en) * 2008-08-13 2011-04-21 Searete Llc Artificial cells
EP2370593B1 (en) * 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
CA2799516C (en) * 2010-08-06 2016-01-05 Canine-Lab.Inc. Immunological function enhancing agent
JP6393186B2 (ja) 2011-05-03 2018-09-19 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
EP2704741B1 (en) 2011-05-03 2017-08-23 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
EP3567102A1 (en) 2012-04-24 2019-11-13 Dan S. Kaufman Method for developing natural killer cells from stem cells
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201604868YA (en) 2013-12-16 2016-07-28 Us Health Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3134437A1 (en) 2014-04-23 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
ES2730325T3 (es) 2014-04-24 2019-11-11 Univ Texas Aplicación de citoblastos pluripotentes inducidos para generar productos de terapia celular adoptiva
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CN107207615A (zh) 2014-11-05 2017-09-26 得克萨斯州大学系统董事会 基因修饰的免疫效应细胞和用于扩增免疫效应细胞的工程化细胞
FR3031519B1 (fr) 2015-01-14 2016-12-30 Arkema France Composition a base de terpolymere electroactif
ES2790725T3 (es) * 2015-03-16 2020-10-29 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Procedimiento de detección de nuevos epítopos de células T inmunogénicas y aislamiento de nuevos receptores de células T específicas de antígeno mediante una biblioteca de células de MHC
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
CA3025667A1 (en) 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
BR112019001327A2 (pt) 2016-07-29 2019-04-30 Juno Therapeutics Inc anticorpos anti-idiotípicos e métodos relacionados
CA3043356A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
CN110891967B (zh) 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
WO2018226897A1 (en) 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
CN120605327A (zh) 2019-11-06 2025-09-09 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
EP4157864A1 (en) 2020-05-27 2023-04-05 Antion Biosciences SA Adapter molecules to re-direct car t cells to an antigen of interest
US12275766B2 (en) 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JP2683461B2 (ja) * 1991-07-05 1997-11-26 住友電気工業株式会社 光ファイバケーブルの製造方法
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1996012009A2 (en) * 1994-10-14 1996-04-25 Tykocinski Mark L Methods for engineering antigen-presenting cells
WO1997046256A1 (en) * 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Also Published As

Publication number Publication date
US7439335B2 (en) 2008-10-21
US7402430B2 (en) 2008-07-22
PT969865E (pt) 2007-02-28
JP2012143245A (ja) 2012-08-02
EP0969865A1 (en) 2000-01-12
US6355479B1 (en) 2002-03-12
ES2278390T3 (es) 2007-08-01
US7074617B1 (en) 2006-07-11
IL126843A (en) 2007-06-17
DE69737070D1 (de) 2007-01-18
CA2254975A1 (en) 1997-12-11
AU3210397A (en) 1998-01-05
AU723355B2 (en) 2000-08-24
WO1997046256A1 (en) 1997-12-11
ATE347588T1 (de) 2006-12-15
IL126843A0 (en) 1999-09-22
US20050054090A1 (en) 2005-03-10
US20050059144A1 (en) 2005-03-17
JP2000511898A (ja) 2000-09-12
EP0969865A4 (en) 2001-07-11
DE69737070T2 (de) 2007-06-21
DK0969865T3 (da) 2007-03-19
EP0969865B1 (en) 2006-12-06
CA2254975C (en) 2008-12-16

Similar Documents

Publication Publication Date Title
JP5006998B2 (ja) Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法
JP3926842B2 (ja) 抗原提示系およびｔ−細胞の活性化方法
EP1249490B1 (en) In vitro activation of cytotoxic T cells
US6001365A (en) In vitro activation of cytotoxic T cells
JP2002509716A (ja) テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
JP2004501165A (ja) Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
TW201247700A (en) Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
US6821778B1 (en) Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
Sato et al. Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease
JP2003506095A (ja) アデノ随伴ウイルス（ａａｖ）で形質導入された遺伝子改変樹状細胞、該細胞の調製方法および該細胞の使用
AU755156B2 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
Foucras et al. Chronic soluble antigen sensitization primes a unique memory/effector T cell repertoire associated with th2 phenotype acquisition in vivo
WO1996012009A2 (en) Methods for engineering antigen-presenting cells
JP2002536008A (ja) 抗原ペプチドコンカテマー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120223

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120329

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120528

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150601

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term